EntryPoint Capital’s Biogen BIIB Stock Holding History

EntryPoint Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,319	Closed	-$465K	–	670
2025 Q3	$465K	Buy	3,319 +258	+8%	+$34.9K	0.18%	194
2025 Q2	$384K	Sell	3,061 -118	-4%	-$14.7K	0.19%	182
2025 Q1	$435K	Buy	3,179 +1,540	+94%	+$220K	0.2%	154
2024 Q4	$251K	Buy	1,639 +55	+3%	+$9.28K	0.11%	478
2024 Q3	$307K	Buy	+1,584	New	+$331K	0.17%	239
2024 Q2	–	Sell	-167	Closed	-$36K	–	929
2024 Q1	$36K	Buy	+167	New	+$39.1K	0.03%	899

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EntryPoint Capital's BIIB Position: Q4 2025 in Review

EntryPoint Capital sold out of Biogen (BIIB) in Q4 2025, closing a stake of 3,319 shares — an estimated $465K sold.

EntryPoint Capital first reported a position in BIIB in Q1 2024 and held it in 6 quarters. The position peaked at $465K in Q3 2025. 997 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

EntryPoint Capital reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
EntryPoint Capital sold 3,319 Biogen shares in Q4 2025, an estimated $465K.
EntryPoint Capital first reported a position in Biogen in Q1 2024 and held it in 6 quarters.
EntryPoint Capital's Biogen position peaked at $465K in Q3 2025.
997 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.